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ABSTRACT
MACROMOLECULAR PRODRUG
FOR THE TREATMENT OF ULCERATIVE COLITIS

Ulcerative colitis is a chronic inflammatory bowel disease affecting the colon.
More than 1 million Americans are affected[1], with the annual economic burden
up to 14.9 billion[2] in the United States. By far, ulcerative colitis still lacks the cure
and the current treatment strategies are limited due to severe side effects and insufficient efficacy. The tofacitinib (Xeljanz) is the only approved oral medication by
for adults with moderately-to-severely-active ulcerative colitis. But the related side
effects and serious infections still have to be resolved. In the previous study in our
lab, the researchers have successfully developed and characterized multiple hydrophilic prodrug formulations (P-Dex-D and P-Tofa). We suppose these prodrugs
can be orally administered with reduced systemic exposure according to their in
vivo release profiles. In this study, these prodrugs are administered orally to dextran sulfate sodium induced ulcerative colitis murine model. The results demonstrated that these drugs can effectively ameliorate colitis and reduced side effects
compared to their parent drugs.
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CHAPTER 1
INTRODUCTION

1.1 Ulcerative colitis
Ulcerative colitis is a chronic, idiopathic inflammatory disease characterized by
disorder of colonic mucosa, starting in the rectum and extending to proximal colon[3]. It is a common and costly disease, affecting approximately 1 million Americans[1], with the annual economic burden up to 14.9 billion[4] in the United States.
The accelerating incidence and prevalence of UC worldwide have made it a global
disease[3, 5]. The disease most commonly presents with bloody stool(hematochezia) and diarrhea, in addition to weight loss, abdominal pain, perianal disease,
signs of malnutrition and so on[6]. Endoscopy is the only way to confirm the diagnosis of UC[3].
The peak age for UC occurrence is around 30 years[7]. Several studies have
revealed that genetics, environment, dietary[8] and smoking factors are playing
important roles in affecting the risk of UC even the etiology is unknown.
UC is incurable and to be continued throughout life[7]. Currently, 5-aminosalicylic acid(5-ASA) is the first-line therapy for mild to moderate ulcerative colitis and
corticosteroids can be added as the second-line treatment when the 5-ASA therapy is ineffective. Moderate to severe disease is managed by immunosuppressants and biological drugs(anti-TNF-α or anti-integrin therapy)[3, 8]. Up to 45% of
UC patients need surgical intervention[9].
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1.2 Main challenges for oral drugs
As we know, the oral route is the most attractive because of its convenience
and patient compliance. However, for ulcerative colitis, oral drugs are of limited
use and have encountered many challenges, due to the complex altered physiological environment caused by inflammation.
An oral drug must traverse the entire digestive tract and stay almost intact before reaching the distal part. Some literature reports that the transit time for inflammatory bowel disease patients in the small intestine is 30% higher than that
in healthy groups (2-6h), while colonic transit time significantly varies from 6-70h,
with faster average duration (24h) compared with that in healthy groups (around
51h)[10].In addition to the adverse transit time, the drugs might be early metabolized in the gastrointestinal tract by enzymatic or microbial degradation. Common
enzymes include as β-glucuronidase, β-xylosidase, glycosidase, dextranase, esterase, cyclodextranase, α-arabinosidase, β-galactosidase, nitroreductase,
azoreductase, deaminase, urea hydroxylase, etc.[11, 12] Normally, luminal PH
rises from the acidic stomach to reach 6 in the duodenum and continues to increase to 7.5 in the ileum. After experiencing a fall to 5.5 in the caecum, PH
gradually rises to 6.7 in the rectum. However, the luminal PH range in inflamed
colon sites has a shift to lower PH, especially for severe colitis[13, 14].
To summarize, oral formulations are challenged by the complexity of various
gastrointestinal barriers. The transit time, mucus charge, particularly pH and enzymes are playing important roles in colon delivery designs.
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1.3 Potential target strategies
Colon target systems can avoid systemic absorption, improve efficacy and bioavailability. To target inflamed colon, the main reported strategies focus on the
design of delayed or controlled release systems, such as charge-, size, time-, pH-,
microflora-, enzyme- dependent systems[15]. However, considerations should be
made during the development process for the varied physiological conditions and
individual variability. Sometimes, conflicting results were reported for the same target mechanisms.
1.4 Animal models
In the field of ulcerative colitis, the dextran sulfate sodium (DSS) model is the
most commonly used murine model. DSS is a polyanionic derivative of dextran. It
works by chemical damage to intestinal epithelium to increase permeability, thus
increasing the exposure of luminal antigens and enteric bacteria[16]. Normally, the
inflammation is limited to colon while the small intestine is involved as a very small
portion[17]. The colitis caused by DSS is like ulcerative colitis from the clinical perspective, characterized by diarrhea, bloody stool, decreased body weight, anemia,
even death. The typical symptoms of colitis usually appear on day 3 and are maximally expressed by day 7[18]. Besides, this model is comparatively simple, cheap
and reproducible. By adjusting the intake concentration and duration, the colitis
could be acute or chronic, moderate or severe.
In our study, we chose two cycles DSS induction process, each cycle contains
7-day DSS intake followed by 7-day normal drinking water for washing out. In this
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case, the first cycle could be considered as the acute phase while the second cycle
as the chronic phase. The therapeutic efficiency could be observed in both phases,
especially under the conditions that conflict treatment results of dexamethasone
were reported.
There are other murine models reported to mimic ulcerative colitis, such as
acetic acid-induced colitis by similar chemical damage mechanism, and oxazolone-induced colitis to induce Th2-type immune response.
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CHAPTER 2
IN VIVO EVALUATION OF P-DEX-D THERAPEUTIC EFFICACY AND
TOXICITY IN ULCERATIVE COLITIS MURINE MODEL
2.1 Introduction
Glucocorticoids are potent drugs that are commonly prescribed for acute
exacerbations as the second-line therapy to induce remission in ulcerative colitis.
Their immunosuppressive and anti-inflammatory effects are realized by their cognate receptor - glucocorticoid receptor[19]. But the longtime use is not recommended due to its undesirable side effects, such as osteoporosis, hypertension,
cataracts, glaucoma, high risk of infections. In the previous study in our lab, the N(2-Hydroxypropyl) methacrylamide (HPMA) and dexamethasone (Dex) copolymers (named P-Dex-D) were synthesized by reversible addition−fragmentation
chain transfer (RAFT) copolymerization as described previously (paper unpublished). On the one hand, the HPMA copolymers are widely used as a safe
hydrophilic macromolecular carrier. On the other hand, according to the slow release profile in vitro, we suppose the ester bond which can be cleaved by increased
esterases and decreased PH environment in inflamed sites possibly improve the
target delivery profile. The study in this chapter further investigated the potential
therapeutic efficacy and possible toxicities of P-Dex-D in the DSS induced murine
model.
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2.2 Materials and instruments
2.2.1 Materials
N-(2-Hydroxypropyl) methacrylamide (HPMA), S,S′-bis(α,α′-dimethyl-α″-acetic
acid)-trithiocarbonate (CTA), were prepared as described previously[20]. Dexamethasone base and dexamethasone sodium phosphate were separately purchased from LETCO medical (Decatur, AL, USA) and Hawkins (Minneapolis,
MN, USA). Dextran sulfate sodium salt (DSS, Mw Ca 40,000) to induce colitis
was provided by Alfa Aesar (Ward Hill, MA, USA). ColoScreen FOB test kit for diagnosing the presence of hematochezia was purchased from Helena Laboratories (Beaumont, Texas, US). The surgical lubricant was purchased from HR
Pharmaceuticals. Inc (Surgilube®, New York, PA, USA). Dulbecco’s modified
eagle medium (DMEM) for cell culture was purchased from Life Technologies
Limited (UK).
C57BL/6J female (8-week old) mice were purchased from Jackson Laboratories. Prior to the start of the study, mice were allowed to acclimate for one week
and given ad libitum access to food and water. All animal experiments were performed according to a protocol approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Nebraska Medical Center (UNMC).
2.2.2 Instruments
Blood glucose was monitored by one Touch Basic blood glucose monitoring
system (Lifescan Europe, Switzerland), accompanied by test strips (Lifescan Europe, Switzerland). The sectioning of paraffin-embedded colon samples was
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completed using a Leica RM2255 rotary microtome (Buffalo Grove, IL, USA).
Histological slides after H&E staining was scanned by a VENTANA iScanner HT
(Tucson, AZ, USA). The colonoscopy was completed by the endoscope, with the
outside diameter of 1.85 mm and LED light all purchased from Gradient Lens
Corporation® (Rochester, NY, USA), and is accompanied with a camera from
Amscope (Irvine, CA, USA). Variable-Speed Peristaltic Tubing Pump was purchased from Fisher Scientific (Hampton, NH, USA) for the air inflation and liquid
perfusion. An X-ray micro-CT system (Skyscan 1172, S/N=10j01156, Hamamatsu C9300 11Mp camera) was used to assess bone quality.
2.2.3 Synthesis and characterization of HPMA copolymer conjugate P-Dex-D
The polymers were prepared as reported previously (Figure 1). The monomer
D dissolved in anhydrous methanol was separately copolymerized with HPMA,
with 2,2″-azobis (isobutyronitrile) (AIBN) as an initiator and S,S′-bis(α,α′-dimethylα″-acetic acid) trithiocarbonate (Chain transfer agent, CTA) as the Reversible addition-fragmentation chain transfer (RAFT) agent under argon at 45 °C for 48 h.
The product was then purified on an LH-20 column and dialyzed followed by lyophilization. The weight average molecular weight (Mw) is around 31.9 ×103 g/mol,
and the polydispersity index (PDI) is 1.48, both of which were determined by size
exclusion chromatography (SEC) with an ÄKTA fast protein liquid chromatography
(FPLC) system. Both the UV-Vis method and hydrolysis method followed by highperformance liquid chromatography (HPLC) measurement were used to determine
the Dex loading, which is 303.66 μmol/g (12%).
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The in vitro release profile in different pH buffers (pH 5.0 acetate buffer, pH 6.0
acetate buffer, pH 7.0, pH7.4 and pH 8.7 phosphate buffer, pH 11 sodium carbonate buffer, human serum and rat serum) demonstrates that the free Dex release in the acidic or neutral environment is very slow. In this case, we can
suppose that the stability of the ester-linked polymers is able to target P-Dex-D to
the distal part of the gastrointestinal tract.
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Figure 2.1 Synthesis route of monomer D and P-Dex-D
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Figure 2.2 Dex release profile in different pH buffers (refer to Dr. Xin Wei’s thesis)
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2.2.4 DSS-induced colitis and drug treatment
Twenty-eight 9-week female C57BL6/J mice were randomly assigned into five
groups. Group 1(n=5) was designated as a healthy control group with normal water
intake and no treatment. Group 2-5 were designed as saline(n=5), dexamethasone
sodium phosphate(n=5, equivalent dex dose=1mg/kg/d), dexamethasone sodium
phosphate(n=8, equivalent dex dose=5mg/kg/d), P-Dex-D(n=5, equivalent dex
dose=5mg/kg/d) treated groups, received 2 cycles of 2% DSS for the chronic colitis
induction. Each cycle includes seven-day continuous 2% DSS in drinking water
followed by a seven-day continuous plain water washout. In each treatment group,
the drug was administrated daily by oral gavage from day 7 post induction to the
end of the study for 21 days.
2.2.5 Evaluation of in vivo anti-inflammatory activity
2.2.5.1 Disease activity index evaluation
Body weight, stool consistency, and hemoccult positivity were examined and
recorded daily for all the animals. The disease activity index (DAI) scores, an indicator of the severity of colitis, were determined based on a standard scoring
system as previously described in the literature (Table 2.1)[21, 22]. The DAI scoring used a 0–3 scale for the change of body weight, and the severity of diarrhea
and the bloody stool.
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Score

Weight loss

Stool consistency

Hemoccult (Blood stool)

0

none

Normal

Negative hemoccult

1

1-5% (>0)

mild soft

Positive hemoccult

2

6-10% (>5)

Very soft; wet

Blood traces in stool visible

Table 2.1 The scoring criteria of the disease activity index based on weight loss,
stool consistency, and bleeding phenomenon
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2.2.5.3 Colonoscopy and Colitis Scoring
Reported classic endoscopic findings in ulcerative colitis include erythema,
vascular pattern loss, granularity, erosion, friability, bleeding, and ulceration[3].
To avoid the inaccurate measurement of DAI caused by contact damage from
the colonoscopy, the colonoscopy experiment was done on day 28. After gentle
air inflation into the colon, the endoscope equipped with light and camera was
used for colonoscopy to image the colon surface. For C57/BL6 mice, the location
for colonoscopy is approximately 1cm away from the anus. The images were
scored by a gastroenterologist (DDE, who was blinded to the treatment groups)
based on the scoring system (Table 2.2) from the previous literature[23].
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Score

Thickening of

Change of vas-

the colon

cular pattern

0

Transparent

Normal

None

None

1

Moderate

Moderate

Little

Moderate

2

Marked

Marked

Marked

Marked

3

Nontransparent Bleeding

Extreme

Extreme

Table 2.2 Endoscopic colitis grading criteria

Fibrin visible

Granularity of the
mucosal surface
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2.2.5.3 Histological assessment of colitis
The mice were euthanized on the 29th day after an oral glucose tolerance
test. Major organs (heart, liver, spleen, lung, kidney, adrenal gland, colon, femur
and lumbar) were collected and fixed in formalin after sacrifice. The length and
weight of colon were measured. The weight of adrenal gland was recorded after
fixation in formalin for 24h.
The longitudinally opened colons were rolled with mucosa outward into a
swiss roll from distal to proximal part. After fixation, the colons were embedded in
paraffin, sectioned (5μm thickness) and stained with hematoxylin and eosin
(H&E). The stained slides were scanned using a high-throughput bright-field slide
scanner and graded by a pathologist (SML, who was blinded to the group arrangement) according to the degree of inflammation, the extent of inflammation,
regeneration, crypt damage and percent involvement. The histological grading
criteria were shown in Table 2.3.
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Parameters

Score

Histological features

Inflammation

0

None

1

Slight

2

Moderate

3

Severe

0

None

1

Mucosa

2

Mucosa and submucosa

3

Transmural

0

Complete regeneration or nor-

Extent

Regeneration

mal tissue

1

Almost complete regeneration

2

Regeneration with crypt depletion

3

Surface epithelium not intact

4

No tissue repair
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Crypt damage

Percent involvement

0

None

1

Basal 1/3 damage

2

Basal 2/3 damage

3

Only surface epithelium lost

4

Entire crypt and epithelium lost

1

1–25%

2

26–50%

3

51–75%

4

76–100%

Table 2.3 Histological Grading Criteria
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2.2.6 Side effects assessment of polymers
2.2.6.1 Adrenal gland observation
It is well known that the chronic administration of high dose exogenous glucocorticoid might cause the adrenal insufficiency[24]. To test the degree of central
suppression and adrenal atrophy, the weight of adrenal gland was recorded after
fixation in formalin for 24h. The reason we did not record the fresh adrenal gland
weight is that the original weight exceeded the precision limit of balance.
2.2.6.2 Oral glucose tolerance test (OGTT)
The diabetogenic effect caused by glucocorticoid administration is often considered as insulin resistance. Briefly, the Dex treatment groups might lack the
ability to regulate blood glucose after glucose intake, due to the insufficient insulin release. To test this, mice were fasted overnight (for 16 hours) on day 28. In
the next morning, they were administrated weight-dependent glucose(1g/kg) by
gavage, and blood glucose on the leg of the mice was measured at 0, 30, and
120 minutes.
2.2.6.3 Micro-CT analysis of bone quality
The femur was collected and fixed in formalin for more than 2 days after euthanasia. The left femur bone quality was analyzed by a Skyscan 1172 micro-CT
system according to the following parameters: voltage, 55kv; current, 181μA;
pixel size, 8.89μm; exposure time, 825ms; filter, 0.5mm aluminum; rotation step,
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0.4 degree; frame average, 4; random movement, 10; 360 rotation, off. The region of interest is the distal femur [25] of 100 slices (0.89mm), 40 slices
(0.36mm) from growth plate to metaphysis.
2.2.6.4 Cytotoxicity study
For cytotoxicity studies, mouse macrophage cell line (J774, ATCC, VA) and
human epithelial cell line (Caco-2, ATCC, VA) were cultured in Dulbecco's Modified Eagle Medium (L-glutamine, high glucose) supplemented with 100 U/mL penicillin, 100 µg/mL streptomycin, and 10% heat-inactivated FBS. During the
experiment, cells were incubated in a humidified 5% CO2 incubator at 37 ºC. Cells
were seeded at 1104 cells/well in 96-well plates and incubated for 24 hours. With
saline as the vehicle, different concentration groups of dexamethasone sodium
phosphate (0.1µM, 1µM, 10µM) and P-Dex-D (1µM, 10µM, 100µM) were added to
each well. The cell viability was determined by MTS cell proliferation colorimetric
assay kit (BioVision, California, USA) at 490nm.
2.2.7 Statistical method
Comparisons were made by one-way ANOVA followed by a post hoc Tukey’s
test for multiple comparisons using GraphPad Prism Software. Data were expressed as means ± standard deviation. P-values ≤0.05 were considered as
statistically significant.
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2.3 Results
2.3.1 Survival curve
No mice were found dead in healthy, saline and P-Dex-D groups while the
mortality in both free Dex treatment groups is significantly high. It is obvious that
a higher dose lead to more severe side effects. Even we set a lower dose free
Dex group, only one mouse survived in the entire free Dex treatment groups.
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Figure 2.3 Survival curve for five treatment groups after DSS induction.
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2.3.2 Disease activity evaluation
The hallmark symptom of UC is bloody diarrhea, sometimes accompanied by
losing weight. In Fig.2.4, the diarrhea was observed instantly on day 1. The body
weight loss and hemoccult were observed from day 5. After one week of treatment, both Dex and P-Dex-D treatment groups showed a trend to ameliorate the
stool consistency. But for the sum of the DAI score, no obvious remission effect
in the acute phase was found in Dex or P-Dex-D treatment groups compared
with the saline group.
In the chronic phase, the second 14-day cycle, the deteriorating conditions in
both Dex groups even lead to the death of mice. Higher Dex dose, earlier and
higher mortality. We suppose it was caused by the severe systemic absorption
effect. Compared with the saline group, the DAI in the P-Dex-D group obviously
has a decreased trend and the statistical difference (P ≤ 0.05) was observed on
day 20. From day 23 to day 28 except day 24, no significant difference was observed between P-Dex-D and healthy groups, while a significant difference (P ≤
0.05) always existed between saline and healthy groups.
Since the inflammation would shorten colon length and thicken bowel wall,
the colon length and weight were measured for further observation. In Fig2.6 A,
no difference was found between groups except that the Dex group showed
shorter colon length. But the colon weight/length ratio was significantly reduced
in the P-Dex-D group compared with the saline group after DSS administration.

23

Figure 2.4 Body weight, stool consistency and hemoccult positivity score change
of mice.
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Figure 2.5 Disease activity index (DAI) in mice. (A) The change of DAI scores
summarized by the sum of three separate scores after DSS induction. (B) DAI
score comparison in four groups on D28 post induction. *, P ≤ 0.05; **, P ≤
0.01.
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Table 2.4 The statistical analyses of the DAI score of the mice from different treatment groups from Day9 to Day 28. One-way analysis of variance (ANOVA), followed by Tukey’s post hoc test to account for multiple comparisons, was used for
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data analysis using GraphPad Prism Software. The statistically significant difference (P ≤ 0.05) between saline and P-Dex-D treatment groups was only found on
D20. (*, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ***, P ≤ 0.001; ****, P ≤ 0.0001).
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Figure 2.6 Quantitative analysis of colon after sacrifice. (A) Colon length at euthanasia; (B) colon weight-to-length ratio at euthanasia. *, P ≤ 0.05; ***, P ≤
0.001.
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2.3.3 Colonoscopy evaluation
The representative recorded images (Fig2.7A) were chosen by a gastroenterologist (DDE). In the healthy control group, the vascular was distinct without any
abnormal signs in the colon. For P-Dex-D treated group, the overall colon conditions on day 28 were similar to that in the healthy group. In contrast, the loss of
vascular, surface irregularities, even bleeding phenomenon were observed in
most mice in saline and Dex-treated groups after three-week treatment. The colonoscopy images demonstrated the significant remission of inflammation in the
P-Dex-D group. The colonoscopy scoring results (Fig2.7B) also showed a decreasing trend of severity in the P-Dex-D treated group, and no statistically significant difference was found between healthy and P-Dex-D groups.
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Figure 2.7 Colonoscopy analysis on day 28. (A) Colonoscopy images recorded in
the distal colon. Blue arrow indicates loss of vascular pattern; red arrow indicates
bleeding; and white arrow indicates irregularities. (B) Colonoscopy score results
evaluated by a gastroenterologist (DDE) according to the endoscopic colitis grading criteria in Table 2.2. *, P ≤ 0.05.
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2.3.4 Histological evaluation
Histology evaluation is the most robust method to observe therapeutic efficacy since the entire colon can be overviewed comprehensively. Intact epithelium, inflammatory cell infiltrates in mucosa and submucosa, severe crypt
damage were observed in saline and Dex-treated groups. Slight inflammation
and negligible crypt depletion were found in the P-Dex-D group. The overall comparison demonstrated the good therapeutic efficacy of the prodrug P-Dex-D. Additionally, the histological observation correlated well with the disease activity
index results and colonoscopy evaluation. The statistically significant difference
was found between the P-Dex-D group and saline or free Dex groups, while no
significant difference was found between the P-Dex-D group and healthy control
groups.
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Figure 2.8 Histology analysis. (A) Representative images after H&E staining at
four times magnification. Blue arrow indicates intact epithelium; red arrow indicates inflammatory cell infiltration; and black arrow indicates crypt damage. (B)
Histological score results evaluated by a pathologist (SML) according to the histological grading criteria in Table 2.3. *, P ≤ 0.05; **, P ≤ 0.01.
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2.3.5 Adrenal gland evaluation
The degree of adrenal atrophy caused by overdose of glucocorticoids can be
well demonstrated by the change of adrenal weight. The adrenal gland weight at
necropsy was too light to be detected by 0.1mg analytical balance. So, we recorded adrenal weight after fixation in formalin. The results indicated a trend of adrenal atrophy after the daily administration of free Dex while there is no reduced
adrenal weight observed in the P-Dex-D group compared with other groups.
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Figure 2.9 Adrenal gland weight evaluation. No statistically significant difference
was found between treatment groups.
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2.3.6 Oral glucose tolerance test
The exclusive hormone, insulin, can lower plasma glucose concentration to
maintain glucose homeostasis in vivo. However, the long-term use of a high dose
of glucocorticoid often results in insulin resistance, leading to the disability to adjust blood glucose[26]. The insulin compensation was clearly observed in mice
treated with free Dex while other groups showed similar normal adaptative blood
glucose profiles. This implies a certain elevated function of islet cells to compensate for the increased Dex-induced peripheral insulin demand[27]. We postulate
that the systemic effect of P-Dex-D is ignorable in the aspect of glucose intolerance.
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Figure 2.10 Blood glucose change after an oral glucose tolerance test.
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2.3.7 Micro-CT analysis for bone quality
The distribution of GC receptors in osteoblasts, growth plate chondrocytes
and other locations in bone marrow leads to osteoporosis by systemic absorption[28]. We analyzed the distal femur (left leg) by Micro-CT and measured bone
architecture parameters: the bone mineral density (BMD), the ratio of bone volume to tissue volume (BV/TV), and trabecular thickness(Th)[29]. No considerable
difference between these groups was observed in bone mineral density and the
ratio of bone volume to tissue volume. The significantly reduced Th value in saline group compared to healthy mice could be contributed to the osteoporosis
caused by ulcerative colitis. Statistical difference was found between saline and
P-Dex-D groups regarding Th, demonstrating the good therapeutic effect and decreased side effect related to bone loss.
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Figure 2.11 Parameters of trabecular bone structure. (A) Bone mineral density. (B)
The ratio of bone volume to tissue volume. (C) Trabecular thickness. *, P ≤ 0.05;
**, P ≤ 0.01; ****, P ≤ 0.0001.

38

Figure 2.12 Trabecular bone structure. (A) An overview of the region of interest
(red region) in the distal femur. (B) The bone structure in ROI (representative images chosen by BMD).
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2.3.8 Cytotoxicity
To evaluate the cytotoxicity in vitro, macrophage and human intestinal epithelial cell lines were used. The drug concentration was determined mainly by the
oral gavage dose. DMEM without FBS was used as vehicle and control groups.
Considering the drug content and slow release of Dex from P-Dex-D in vitro, we
selected 100µM P-Dex-D to correspond to 10µM Dex dosage. In this study, we
found no evidence in relation to cytotoxicity in two cells.
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Figure 2.13 Cytotoxicity evaluation. (A) Cell viability in mouse macrophage-like
cells(J774). (B) Cell viability in the intestinal epithelial cell line (Caco-2). No statistically significant difference was found between groups by one-way analysis of
variance.
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2.4 Discussion
Ulcerative colitis is a multifactorial chronic inflammatory disease that mainly
affects large intestine which can’t be cured. It is characterized by mucosal inflammation, starting from rectum and extending to the proximal colon. The hallmark
phenomenon is bloody diarrhea. As anti-inflammatory agents, glucocorticoids are
often used to treat mild to moderate ulcerative colitis clinically by topical or systemic administration as the second-line therapy. Although it effectively induces
remission, Dex is not effective in maintaining remission. Besides, as a low molecular weight drug, high dosage and long-term use of Dex often result in serious
adverse effects due to limited targeting of inflamed sites.
For oral therapy, the multiple physiological barriers, various enzyme degradation, complex PH environment, shorter colon transit, all raise challenges for oral
formulation development. Currently published strategies mainly focused on PH-,
size-, charge-, time-, enzyme- dependent delivery systems and some significantly increased clinical remission. Literature has also reported some advanced
research of oral steroids to minimize systemic activity by utilizing first-pass liver
metabolism or prolonged release profile. Our previous study successfully developed the HPMA-conjugated prodrug with cleavable ester bond. The HPMAbased conjugate with comparatively high drug loading (13% Dex content) significantly improved the solubility. The surface PH of colonic mucosa ranging from
7.1 to 7.5[30] is consistently considered high in vivo. The intraluminal PH in the
colon is also comparatively higher than other parts in the gastrointestinal tract,
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except for extremely low PH (2-4) observed in severe active colitis. The slow release profile(approximately 1% per day) in acidic PH environment enables the
delivery of the most intact drug to the distal gastrointestinal tract and further controlled release by upregulated esterase in inflammatory sites[31]. Additionally,
Passive accumulation could be achieved by the leaky endothelium, which contributes to higher permeability of conjugates compared to healthy tissues. So, we
suppose that the design of prodrug P-Dex-D potentially targets to the inflamed
colon, reduces systemic exposure, achieves controlled release by enzyme-responsive degradation.
In the present study, we evaluated the therapeutic effect and potential side effects in a DSS-induced murine model. Compared to the high mortality in free
Dex-treated groups, all mice survived in the P-Dex-D treatment group. This implies the reduced systemic exposure and potential target to inflamed colon sites.
The daily observation of the DAI score showed a trend of P-Dex-D treatment to
ameliorate inflammation compared to other treatment groups in the aspects of
body weight and bloody diarrhea, especially in the second cycle. Although no
statistically significant difference in colonoscopy score was found between saline
and P-Dex-D groups, there is no statistically significant difference observed between healthy and P-Dex-D groups. The wide PH range and conflicting observation of PH change in the colon might imply the inter-individual variability in the
endoscopy due to different Dex release profiles[32]. The statistically significant
difference between P-Dex-D and saline groups in colon density, histology score
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after sacrifice further demonstrated P-Dex-D effectively induces remission. However, the complete resolution was not achieved with P-Dex-D treatment even
there is no statistical difference between P-Dex-D treated group and healthy controls from the aspects of DAI score on day 28, histological and colonoscopy evaluation. Obviously, additional dose escalation experiment and different chronic
strategies are necessary to further advance P-Dex-D treatment.
In addition, to assess the underlying side effects, we compared the adrenal
weight change, oral glucose tolerance, bone loss in the distal femur and cytotoxicity. Expectedly, there is a trend for free Dex group to cause adrenal gland atrophy and overexpressed glucose tolerance, while the observation of P-Dex-D
treated mice corresponded to those levels in healthy and saline-treated mice.
One of the severe side effects caused by GC is osteoporosis. No bone loss was
found in the P-Dex-D treated group. Regarding the cell cytotoxicity in macrophage or human epithelial cells, no cytotoxicity was found after P-Dex-D treatment. In a word, a comparative safety profile was proved by the above
experiments.
DSS model is chemical-induced colitis characterized by leaky epithelium in
the colon. It has been widely perceived as a good colitis model mostly owing to
the similarities to human colitis in aspects of pathology. From this murine model,
both the acute phase and chronic phase could be utilized to evaluate therapeutic
efficacy. The little therapeutic efficacy in Dex and P-Dex-D groups in the first cycle observed from DAI score corresponds to some reports that Dex was not
working in the acute phase. Further improvement of drug administration duration
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on the chronic model is needed. To comprehensively investigate the therapeutic
efficacy and side effects, other murine models by different induction mechanism
could be used to evaluate P-Dex-D treatment, such as the T-bet-/- RAG2-/- Ulcerative Colitis (TRUC) model, which spontaneously develops juvenile ulcerative
colitis by damaging transcriptional regulatory T-bet in RAG2-/- mice[33].
To better understand of drug release in vivo, the release profiles in acidic
stomach PH, in the presence or absence of esterase respectively would be further investigated. In addition, the on-going optical imaging-based P-Dex-D biodistribution and immunohistochemistry analysis are expected to profile more details
in vivo.
Even non-toxic and biocompatible HPMA benefits hydrophobic drug delivery,
considerations should be taken due to its non-biodegradable property. In the present study, the molecular weight was designed at 35kDa, which is below the molecular weight threshold of 45kDa for HPMA copolymer in the aspect of
elimination. But the slow excretion rate via the hepatobiliary route still raises a
safety concern, especially for prolonged use in chronic disease. To address the
underlying weakness, a degradable HPMA copolymer is supposed to be further
developed.
2.5 Conclusion
In this study, the therapeutic efficacy of the HPMA copolymer P-Dex-D was
successfully validated in the treatment of the DSS-induced chronic ulcerative colitis murine model. We postulate the potential target delivery mechanism is the
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passive targeting to the leaky epithelium and controlled release of Dex by esterase responsive ester bond in the copolymer. The safety profile further addressed
the excess systemic exposure of free Dex. The superior therapeutic efficacy and
desirable safety properties make it a potential drug in the treatment of ulcerative
colitis.
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CHAPTER 3
IN VIVO EVALUATION OF P-TOFA THERAPEUTIC EFFICACY AND
TOXICITY IN ULCERATIVE COLITIS MURINE MODEL

3.1 Introduction
As mentioned in chapter 2, ulcerative colitis still lacks the cure, especially in
the aspect of oral formulations. As the first developed Janus Kinase inhibitor, tofacitinib (Tofa) was used to treat moderately to severely active rheumatoid arthritis as add-on therapy of methotrexate. It effectively inhibits JAK3, with a lower
extent to inhibit JAK1 and JAK2, to block the Janus Kinase pathway involved in
proinflammatory cytokine signaling[34]. In 2018, it (Xeljanz) was approved by the
Food and Drug Administration (FDA) as the first oral medication for adults with
moderately and severely active ulcerative colitis[35]. But the related serious infections and side effects, such as neutropenia and thrombocytopenia caused by
JAK2 involvement, still must be resolved.
In our previous study, a macromolecular Tofa prodrug (P-Tofa) was synthesized and the significant inflammation amelioration by intravenous administration
was validated in a murine colitis model. To further investigate the potential in oral
formulations, the therapeutic efficacy was evaluated in a DSS-induced murine
model.
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3.2 Materials and Instruments
3.2.1 Materials
N-(2-Hydroxypropyl) methacrylamide (HPMA), S,S′-bis(α,α′-dimethyl-α″-acetic
acid)-trithiocarbonate (CTA), were prepared as described previously. (synthesis
and evaluation of a well-defined HPMA copolymer) Tofacitinib citrate and Tofacitinib base were both purchased from Jinlan Pharm-Drugs Technology Co, Ltd.
(Hangzhou, China). IRDye® 800CW carboxylate was provided by LI-COR, Inc.
(Lincoln, NE, USA). DSS and related materials such as hemoccult test kit were
prepared as described in 2.2.1.
C57BL/6J female (8-week old) mice were purchased from Jackson Laboratories and used for the therapeutic efficacy study. Swiss Webster male (8-week
old) mice were purchased from Charles River Laboratories and used for biodistribution study. Both mice were fed a standard diet ad libitum and maintained under
standard housing conditions in the University of Nebraska Medical Center
(UNMC) animal facility. All animal experiments were performed according to a
protocol approved by the Institutional Animal Care and Use Committee (IACUC)
of the UNMC.
3.2.2 Instruments
The biodistribution part was imaged by LI-COR Pearl® Impulse small animal
imaging system (Lincoln, NE, USA). Other instruments were the same as mentioned in 2.2.2.

48

3.2.3 Synthesis and characterization of P-Tofa
As reported previously[1, 36], HPMA and Tofa-containing monomer (molar ratio=14:1) were dissolved in anhydrous dimethyl sulfoxide (DMSO) with AIBN as
initiator and S,S′-bis(α, α′-dimethyl-α″-acetic acid)-trithiocarbonate (CTA) as the
RAFT agent. The reaction was under the protection of argon and polymerized at
60 °C for 40 hr. The resulting polymer was first purified by precipitation in acetone/diethyl ether (v/v = 1:1, 200 mL) twice to remove the unreacted low molecular weight compounds, followed by dialysis with 25 kDa weight cutoff dialysis
tubing in distilled water and final lyophilization. The weight average molecular
weight (Mw) is around 30.4 ×103 g/mol, and polydispersity index (PDI) is 1.32,
both of which were determined by size exclusion chromatography (SEC) with an
ÄKTA fast protein liquid chromatography (FPLC) system.
To quantify Tofa loading, P-Tofa was hydrolyzed in 0.01 N NaOH in CH3OH
overnight, followed by neutralization and analysis triplicate with HPLC system
(mobile phase: acetonitrile/water = 3/1; detection, UV 284 nm; flow rate = 1
mL/min; injection volume = 20 μL). Finally, the Tofa loading in P-Tofa was found
to be 14.07 wt%. The release rates of Tofa from P-Tofa prodrug at pH = 5.5 and
7.4 were averaged at ~1.5%, 2% per day, respectively (Fig 3.2).
P-Tofa labeled with IRDye® 800CW was achieved by dissolving IRDye®
800CW carboxylate, N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and hydroxybenzotriazole (HOBtl) in DMF in dark at 21 C, followed
by stirring for 30 min. DIPEA and P-Tofa-APMA (from the RAFT polymerization
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of HPMA, Tofa-containing monomer, APMA, AIBN, CTA in DMSO at 60 °C for 40
hr) in DMF were added into the reaction mixture and then stirred overnight. The
reaction solution was dialyzed to remove DMF and low molecular weight reactants. P-Tofa-IRDye was then obtained via lyophilization. The final IRDye 800CW
content is 8 × 10–6 mol/g of the conjugate.
The data in this synthesis and characterization section were all from the previous study before this experiment[36].
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Figure 3.1 A macromolecular prodrug of Tofacitinib (P-Tofa) [36]. (A) The synthesis of HEMA-Tofa monomer; (B) The synthesis of P-Tofa.
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Figure 3.2 Tofa release profile in different PH conditions[36].
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3.2.4 DSS-induced colitis and drug treatment
Twenty 9-week female C57BL6/J mice were randomly assigned into four
groups. Group 1(n=5) was designated as a healthy control group with normal water
intake and no treatment. Group 2-4 were designed as saline (n=5), Tofa (n=5,
10mg/kg/d), P-Tofa (n=5, equivalent Tofa dose=10mg/kg/d) treated groups, received 2 cycles of 2% DSS for the chronic colitis induction. Each cycle includes
seven-day continuous 2% DSS in drinking water followed by a seven-day continuous plain water washout. In each treatment group, the drug was administrated
daily by oral gavage from day 8 post induction to the end of the study for 21 days.
3.2.5 Evaluation of in vivo therapeutic activity
The entire process and scoring criteria of disease activity index evaluation,
colonoscopy evaluation, histological assessment were the same as that described in chapter 2.2.5.
3.2.6 Biodistribution analysis of P-Tofa by optical imaging
9-week male Swiss Webster mice (three mice per group per time point) were
used for the optical imaging study. They were randomly divided into two groups:
the healthy control group with normal water intake and the DSS group with 5%
DSS in drinking water for five days. On day 6, all mice were all orally (by 22G gavage needle) administrated weight-dependent dosage of P-Tofa-IRDye
(40mg/kg) at the same time. They were euthanized 2h, 4h, 24h separately posttreatment and the major organs (heart, liver, spleen, lung, kidney, adrenal gland,
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mesenchymal lymph nodes, small intestine, and colon) were collected and imagined by Pearl® Impulse small animal imaging system to evaluate the biodistribution of the IRDye-labeled P-Tofa. For better observation, the stools in the colon
and small intestine were removed followed by a through washing process with
saline.
3.2.7 Statistical methods
Comparisons for DAI score and biodistribution analysis were made by twoway ANOVA test using GraphPad Prism Software. Other comparisons were
made by one-way ANOVA followed by a post hoc Tukey’s test for multiple comparisons using GraphPad Prism Software. Data were expressed as means ±
standard deviation. P-values ≤0.05 were considered as statistically significant.
3.3 Results
3.3.1 Disease activity index evaluation
During the entire treatment process, no mice were found dead. In the first cycle,
little therapeutic efficacy in Tofa or P-Tofa treated groups was observed when compared with the saline control group. During the period of DSS exposure (day 15 to
day 21) in the following chronic phase, the free Tofa treated group showed a trend
of reduced DAI score while the undulant change of the sum of the score was observed in P-Tofa group. In the last seven-day washout period, the steadily and
faster decline in the P-Tofa treatment group was found compared to other groups.
The Tofa treated group also has a lower score continuously in the last four days
than that in the saline group, but still higher than that in the P-Tofa group. On day
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25 post induction, saline and P-Tofa treatment group has statistical difference (**,
P ≤ 0.01). The obvious amelioration of DAI by P-Tofa monitored in the last cycle
indicated its potential therapeutic efficacy.
To quantify the symptom of shorten colon length and thicken bowel wall, we
measured the colon length and weight at necropsy. Although there is no statistical
difference found in colon length, the ratio of colon weight to length did illustrate
some differences. Compared to saline control, both Tofa and P-Tofa showed significant improvement in colon conditions. The statistical difference (*, P ≤ 0.05)
observed between Tofa and P-Tofa group indicated better efficacy of P-Tofa of the
equivalent Tofa dosage. However, the statistical difference (*, P ≤ 0.05) between
healthy and P-Tofa group demonstrated the complete resolution of chronic colitis
was not achieved.
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Figure 3.3 Disease activity index (DAI) in mice. (A) The change of DAI scores
summarized by the sum of three separate scores after DSS induction. (B) DAI
score comparison in four groups on D28 post induction.

56

Healthy vs.
Saline
Healthy vs.
Free Tofa
Healthy vs.
P-Tofa
Saline vs.
Free Tofa
Saline vs.
P-Tofa
Free Tofa
vs. P-Tofa

D22

D23

D24

D25

D26

D27

D28

****

****

**

****

**

**

*

****

****

**

*

*

ns

*

***

*

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

**

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

Table 3.1 The statistical analyses of the DAI score of the mice from different treatment groups from Day22 to Day 28. Two-way analysis of variance (ANOVA) was
used for data analysis using GraphPad Prism Software. (*, P ≤ 0.05; **, P ≤ 0.01;
***, P ≤ 0.001; ****, P ≤ 0.0001). On day 25 post induction, saline and P-Tofa treatment group has statistical difference (**, P ≤ 0.01).
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Figure 3.4 Quantitative analysis of colon at euthanasia. (A) Colon length at euthanasia; (B) colon weight-to-length ratio at euthanasia. (*, P ≤ 0.05; ***, P ≤
0.001; ****, P ≤0.0001)
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3.3.2 Colonoscopy evaluation
The representative recorded images (Fig3.5A) were chosen by a gastroenterologist (DDE). In the healthy control group, the vascular was distinct without any
abnormal signs in the colon. The bleeding phenomenon was observed in most
mice treated by saline, no more than half of mice treated by Tofa. However, the
loss of vascular pattern and visible granularity were more common in Tofa and PTofa groups, leading to higher colonoscopy score compared to saline treatment
group. The unexpected statistical difference existed between saline and both
Tofa and P-Tofa groups, which is totally in contrast to the observation from daily
DAI and colon analysis. The conflicting endoscopic results might partly attribute
to the insufficient record of distal colon conditions. No recorded video was a point
of weakness affecting the overall judgment in this study.
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Figure 3.5 Colonoscopy analysis on day 28. (A) Representative colonoscopy images recorded in the distal colon. (B) Colonoscopy score results evaluated by a
gastroenterologist (DDE) according to the endoscopic colitis grading criteria in
Table 2.2. (*, P ≤ 0.05; **, P ≤ 0.01; ****, P ≤0.0001)
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3.3.3 Histological evaluation
The histology evaluation was achieved from the H&E staining of colon tissue.
The most severity of mucosal erosion and inflammation involvement were observed in the saline group. Mild crypt damage and cell infiltration were observed
in Tofa and P-Tofa groups. Comparatively, the overall severity of colonic inflammation in both Tofa and P-Tofa groups were reduced, which corresponded to the
trend in histological score accessed by a pathologist (SML). However, no statistical difference was found between each group. The statistical analysis illustrated
that the saline-treated group had comparatively good recovery ability.
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Figure 3.6 Histology analysis. (A) Representative images after H&E staining at
four times magnification. (B) Histological score results evaluated by a pathologist
(SML) according to the histological grading criteria in Table 2.3.
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3.3.4 Biodistribution study
The near-infrared optical imaging-based analysis was used to analyze the PTofa biodistribution in vivo and prove the potency of target delivery. At each time
point post P-Tofa-IRDye administration, no drug retention was observed in major
organs, including heart, liver, spleen, lung, kidney, adrenal gland and mesenchymal lymph nodes. Despite some signals monitored in feces, stomach, and cecum, prodrug was found to accumulate mainly in the colon. There is some signal
observed in the small intestine. The stronger intensity in the small intestine in the
sick group than healthy mice could be attributed to the partial damage to the epithelium in small intestine caused by DSS exposure. The statistical difference observed between healthy and DSS induced groups in both inflamed colon and the
small intestine demonstrated its specific target to inflammatory tissue. From the
data after one-day administration, we found the prodrug was all degraded or
even eliminated.
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Figure 3.7 Near-infrared optical imaging-based analysis of P-Tofa biodistribution
in the colon. (A) Representative images at 2h, 4h, 24h post P-Tofa-IRDye administration. (B) Quantitative analysis of intensity remaining in the colon. Two-way
ANOVA analysis was used, ****, P ≤0.0001.
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Figure 3.8 Near-infrared optical imaging-based analysis of P-Tofa biodistribution
in the small intestine. (A) Representative images at 2h, 4h, 24h post P-TofaIRDye administration. (B) Quantitative analysis of intensity remaining in the small
intestine. (C) Comparison of quantitative intensity in the colon and intestine. Twoway ANOVA analysis was used, *, P ≤ 0.05; **, P ≤ 0.01.
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3.4 Discussion
As the first approved oral medication of UC, Tofa effectively induces and
maintains remission[1]. However, the dose-dependent toxicities caused by simultaneous targeting of other JAK family members raise the concern in clinical use.
Clinical studies reported that 3.8% of patients discontinued Tofa treatment in the
first three months due to side effects, represented by pneumonia and shingles[35]. We supposed P-Tofa might achieve target drug delivery by the cleavable carbamate linker. In the present study, a DSS-induced chronic colitis model
was used.
From daily DAI observation in the second cycle, there was a trend that both
Tofa and P-Tofa groups effectively ameliorated colitis. As indicated in the DAI
score on day 28 and colon density, P-Tofa showed better therapeutic efficacy
than an equivalent dosage of free Tofa. A similar trend was found in histological
results. However, these results contrasted to endoscopic evaluation. Even bloody
phenomenon was more common in the saline-treated group, the granularity and
thicken colon were more often observed in P-Tofa, especially Tofa treated mice.
According to an explanation given by the gastroenterologist, only photos without
video was the main drawback for an overall evaluation. In this case, the histological evaluation became more robust.
In the biodistribution study[1], we sacrificed the mice at 2h, 4h and 24h post
P-Tofa-IRDye gavage. No signal was found in organs and mesenchymal lymph
nodes. As expected, after 2h, prodrug became accumulate in inflamed sites.
Since the DSS induced colitis slightly damaged small intestine, the significantly
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stronger signal was observed in both small intestine and colon in DSS-induced
mice compared to healthy control. After one-day administration, the prodrug was
no more observed in vivo. The result revealed the potential inflammation targeting effect of P-Tofa.
As mention in chapter 2, further evaluation should be done in other murine
models. Besides, considering the excretion of prodrug wrapped in the feces, a
dose escalation study is necessary.
From the previous study, no cytotoxicity of P-Tofa was found in macrophage
(J774) and human epithelial cells (Caco-2). But this study still lacks side effects
evaluation, such as white blood cell count. More comprehensive toxicities are expected to be completed under the premise of further improved efficacy.
3.5 Conclusion
To conclude, a macromolecular prodrug of JAK inhibitor (P-Tofa) was evaluated in a DSS-induced colitis model. It showed superior therapeutic efficacy compared to dose equivalent Tofa treatment. Due to the conflict endoscopic results,
more efficacy and safety evaluation is necessary to further explore its potential
as an alternative therapy for Tofa.
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CHAPTER 4
SUMMARY
4.1 Conclusion
Based on HPMA macromolecular conjugates (P-Dex and P-Tofa) developed in
the previous study, this study focused on the validation of therapeutic efficacy and
evaluation of the safety profile. Both prodrugs showed significantly improved efficacy compared with their parent drugs.
4.2 Future plan
In the future, the optimization of polymeric carrier systems may also be explored for the further improved treatment of ulcerative colitis. The further investment of the dosage and murine models would be done to fully establish their
potential as a new therapy to ameliorate ulcerative colitis.
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